Holen Sie sich die Stockscreener-App
16.80
6.19%
0.98
Schlusskurs vom Vortag:
$15.82
Offen:
$18.6
24-Stunden-Volumen:
4.99M
Relative Volume:
3.81
Marktkapitalisierung:
$849.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-4.5528
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
+8.67%
1M Leistung:
+3.96%
6M Leistung:
+5.07%
1J Leistung:
+103.88%
1-Tages-Spanne:
$16.01
$19.00
1-Wochen-Bereich:
$15.12
$19.00
52-Wochen-Spanne:
$7.30
$19.00
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
16.80 | 799.64M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Bestätigt | Needham | Buy |
| 2026-01-06 | Bestätigt | Needham | Buy |
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt? - simplywall.st
Kalvista Stock Surges On Strong EKTERLY Uptake - Nasdaq
KalVista Details Early Sales, Prescriber Uptake For Newly Approved DrugKalVista Pharmaceuticals (NASDAQ:KALV) - Benzinga
Stock Market Today: Dow, Nasdaq 100 And S&P 500 Futures Gain After December Jobs Data— General Motors, Tilray In Focus (UPDATED) - Benzinga
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales - Investing.com
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales - Investing.com India
KalVista reports $49M in 2025 Ekterly revenue, shares rise - MSN
KalVista Pharmaceuticals (KALV) Receives Buy Rating with Increas - GuruFocus
Kalvista stock price target raised to $29 from $28 at Citizens on strong Ekterly launch - Investing.com UK
KALV: Needham Raises Price Target to $35, Maintains Buy Rating | - GuruFocus
KalVista Stock Pre-Market (+14%) : Reports Strong EKTERLY Launch Revenue - Trefis
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart - MSN
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart - Stocktwits
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY By Investing.com - Investing.com South Africa
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY - Investing.com Canada
KalVista reports $35 million Q4 revenue for oral HAE treatment EKTERLY - Investing.com Australia
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results - The Joplin Globe
Will KalVista Pharmaceuticals Inc. (4XC1) stock sustain bullish trend into 2025Weekly Gains Summary & Weekly Breakout Watchlists - ulpravda.ru
How KalVista Pharmaceuticals Inc. (4XC1) stock moves in volatile trading sessions - bollywoodhelpline.com
Aug Sectors: Is KalVista Pharmaceuticals Inc stock supported by innovation pipeline2025 Retail Activity & Technical Buy Zone Confirmation - moha.gov.vn
Needham raises Kalvista Pharmaceuticals stock price target on Ekterly launch success - Investing.com Nigeria
KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $32.00 - MarketBeat
KalVista Pharmaceuticals (KALV): Needham Raises Price Target to $32 | KALV Stock News - GuruFocus
Millennium Management LLC Acquires Additional Shares in KalVista Pharmaceuticals - GuruFocus
KalVista Pharmaceuticals Inc 4XC1 Stock Analysis and ForecastTrading Volume Trends & No Fee. No Catch. Just Smart Investment Ideas - Early Times
2025 Drug Launches Underscore Commercial Headwinds For New Products - Citeline News & Insights
Precision Trading with Kalvista Pharmaceuticals Inc. (KALV) Risk Zones - Stock Traders Daily
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 5.1% HigherShould You Buy? - MarketBeat
KalVista Pharmaceuticals, Inc.Common Stock (NQ: KALV - FinancialContent
KalVista Pharmaceuticals (KALV) Gains Approval for EKTERLY in Ja - GuruFocus
Japan approves KalVista’s oral HAE treatment Ekterly By Investing.com - Investing.com Canada
KalVista (KALV) Gains Approval for Ekterly in Japan - GuruFocus
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (KALV) Movement - Stock Traders Daily
Will KalVista Pharmaceuticals Inc. stock attract ESG investors2025 Sector Review & Smart Money Movement Tracker - Улправда
KalVista Pharmaceuticals Earnings Notes - Trefis
KalVista Shares Navigate Post-Rally Consolidation Phase - AD HOC NEWS
Sentiment Review: How KalVista Pharmaceuticals Inc. (4XC1) stock expands through international marketsTrade Risk Assessment & Stepwise Swing Trade Plans - Улправда
Why KalVista Pharmaceuticals Inc. stock is favored by pension funds2025 Bull vs Bear & Free Community Consensus Stock Picks - DonanımHaber
Can KalVista Pharmaceuticals Inc. stock outperform in 2025 bull marketJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - DonanımHaber
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV) and Novan (NOVN) - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year HighHere's Why - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $898,000 Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Stempoint Capital LP Cuts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Discipline and Rules-Based Execution in KALV Response - news.stocktradersdaily.com
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $120,423.94 in Stock - MarketBeat
Possible Bearish Signals With KalVista Pharmaceuticals Insiders Disposing Stock - simplywall.st
Pharvaris surges, pulling KalVista out of a slump, on promising new HAE treatment - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kalvista Pharmaceuticals Inc-Aktie (KALV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sweeny Nicole | Chief Commercial Officer |
Nov 24 '25 |
Sale |
13.45 |
3,813 |
51,289 |
39,728 |
| Piekos Brian | Chief Financial Officer |
Nov 24 '25 |
Sale |
13.45 |
4,471 |
60,139 |
10,529 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 24 '25 |
Sale |
13.45 |
4,331 |
58,256 |
223,508 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Nov 24 '25 |
Sale |
13.45 |
5,296 |
71,236 |
131,831 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 24 '25 |
Sale |
13.45 |
10,940 |
147,154 |
416,189 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 20 '25 |
Option Exercise |
0.00 |
87,390 |
376 |
220,964 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 18 '25 |
Sale |
14.48 |
4,466 |
64,665 |
403,879 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 18 '25 |
Sale |
14.48 |
2,683 |
38,848 |
133,574 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Nov 18 '25 |
Sale |
14.48 |
3,075 |
44,524 |
125,877 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 12 '25 |
Sale |
11.55 |
3,328 |
38,438 |
398,981 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):